You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDimenhydrinate
Accession NumberDB00985  (APRD00924)
TypeSmall Molecule
GroupsApproved
DescriptionDimenhydrinate (Dramamine, Gravol and Vertirosan) is an over-the-counter drug used to prevent motion sickness. It is closely related to diphenhydramine HCl, or Benadryl. It is primarily a H1-antagonist, but also possesses an antimuscarinic effect.
Structure
Thumb
Synonyms
(O-Benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
8-chloro-1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
Benzhydryl-beta-dimethylaminoethylether 8-chlorotheophylline
beta-Dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
Dimenhidrinato
Dimenhydrinatum
Diphenhydramine 8-chlorotheophyllinate
Diphenhydramine 8-chlorotheophylline
Diphenhydramine theoclate
Diphenhydrinate
N,N-Dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
O-Benzhydryldimethylaminoethanol 8-chlorotheophyllinate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alveda Dimenhydrinate Injection USP 50 mg/mlsolution50 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2016-01-28Not applicableCanada
Dimenhydrinate Inj 10mgliquid10 mgintravenousSandoz Canada Incorporated1973-12-31Not applicableCanada
Dimenhydrinate Inj 10mg/mlliquid10 mgintravenousAstra Pharma Inc.1986-12-311999-07-29Canada
Dimenhydrinate Inj 50mg USPliquid50 mgintramuscular; intravenousSandoz Canada Incorporated1973-12-31Not applicableCanada
Dimenhydrinate Injection 50mg/mlsolution50 mgintramuscular; intravenousAstrazeneca Canada Inc1986-12-312005-05-31Canada
Dimenhydrinate Injection USP 250mg/5ml (50mg/ml)solution50 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2008-06-26Not applicableCanada
Dimenhydrinate Injection USP With Preservativesolution50 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2016-01-28Not applicableCanada
Dimenhydrinate Injection, USPsolution50 mgintramuscular; intravenousMylan Pharmaceuticals Ulc1994-12-31Not applicableCanada
Gravol Imsolution50 mgintramuscularChurch & Dwight Canada Corp1953-12-31Not applicableCanada
Gravol IV Ampoulessolution10 mgintravenousChurch & Dwight Canada Corp1953-12-312008-07-30Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dimenhydrinateinjection, solution50 mg/mLintramuscular; intravenousAPP Pharmaceuticals, LLC2004-11-29Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Airmit Acetablet25 mg/1oralSato Pharmaceutical Co., Ltd.2005-03-11Not applicableUs
Anti-nauseanttablet50 mgoralPharmascience Inc2002-08-23Not applicableCanada
Anti-nauseanttablet50 mgoralPharmascience IncNot applicableNot applicableCanada
Anti-nauseanttablet50 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Anti-nauseanttablet50 mgoralApotex Inc2013-07-02Not applicableCanada
Anti-nauseanttablet50 mgoralVita Health Products Inc2000-05-01Not applicableCanada
Anti-nauseant Tablettablet50 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1998-05-262008-08-07Canada
Apo Dimenhydrinate Tab 50mgtablet50 mgoralApotex Inc1977-12-31Not applicableCanada
Children's Motion Sickness Liqliquid15 mgoralTanta Pharmaceuticals Inc1996-12-31Not applicableCanada
Dimenhydrinatetablet50 mg/1oralCarilion Materials Management2004-03-01Not applicableUs
Dimenhydrinatetablet50 mg/1oralQualitest Pharmaceuticals2004-03-01Not applicableUs
Dimenhydrinatetablet50 mg/1oralQualitest Pharmaceuticals2015-06-05Not applicableUs
Dimenhydrinatetablet, film coated50 mg/1oralTime Cap Labs, Inc2011-01-28Not applicableUs
Dimenhydrinatetablet50 mg/1oralContract Pharmacal Corp2001-01-12Not applicableUs
Dimenhydrinatetablet50 mg/1oralA S Medication Solutions Llc2004-03-01Not applicableUs
Dimenhydrinate 50mgtablet50 mgoralPro Doc Limitee1963-12-312010-07-13Canada
Dimenhydrinate Capsulescapsule50 mgoralApotex Inc2014-07-24Not applicableCanada
Dimenhydrinate Liquid for Childrenliquid15 mgoralSupplements Aromatik Inc.Not applicableNot applicableCanada
Dimenhydrinate Tab 50mgtablet50 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Dimenhydrinate Tab 50mg USPtablet50 mgoralPharmetics (2011) Inc1995-12-312000-08-21Canada
Dimenhydrinate Tablet USP 50mgtablet50 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Dimenhydrinate Tabletstablet50 mgoralTanta Pharmaceuticals Inc2001-11-06Not applicableCanada
Dinatetablet50.0 mgoralJaapharm Canada Inc.1999-05-20Not applicableCanada
Dramaminetablet, chewable50 mg/1oralLil' Drug Store Products, Inc.2010-05-10Not applicableUs
Dramamine for Kidstablet, chewable25 mg/1oralMedtech Products Inc.2012-02-15Not applicableUs
Dramamine Orangetablet, chewable50 mg/1oralMedtech Products Inc.2012-01-15Not applicableUs
Dramamine Original Formulatablet50 mg/1oralMedtech Products Inc.2012-01-15Not applicableUs
Driminatetablet50 mg/1oralAvera Mc Kennan Hospital2015-04-27Not applicableUs
Driminatetablet50 mg/1oralMajor Pharmaceuticals1992-12-01Not applicableUs
Gravol Capsules Long Acting 75mgcapsule (sustained-release)75 mgoralChurch & Dwight Canada Corp1956-12-312005-08-01Canada
Gravol Comfort Shaped Suppositoriessuppository100 mgrectalChurch & Dwight Canada Corp1951-12-31Not applicableCanada
Gravol Easy To Swallow Tabletstablet50 mgoralChurch & Dwight Canada Corp1980-12-31Not applicableCanada
Gravol Filmkote Tab 15mgtablet15 mgoralChurch & Dwight Canada Corp1980-12-312014-06-26Canada
Gravol Immediate Release & Long Acting Capletstablet (combined release)100 mgoralChurch & Dwight Canada Corp2005-02-10Not applicableCanada
Gravol Junior Suppositories 50mgsuppository50 mgrectalChurch & Dwight Canada Corp1951-12-312008-07-30Canada
Gravol Kids Comfort Shaped Suppositoriessuppository25 mgrectalChurch & Dwight Canada Corp1989-12-31Not applicableCanada
Gravol Kids Liquidsyrup15 mgoralChurch & Dwight Canada Corp1951-12-31Not applicableCanada
Gravol Kids Quick Dissolve Chewabletablet (chewable)15 mgoralChurch & Dwight Canada Corp2012-11-14Not applicableCanada
Gravol Long Acting Caplettablet (extended-release)75 mgoralChurch & Dwight Canada Corp2002-09-232005-08-01Canada
Gravol Quick Dissolve Chewabletablet (chewable)50 mgoralChurch & Dwight Canada Corp2012-11-14Not applicableCanada
Gravol Tab 25mgtablet25 mgoralChurch & Dwight Canada Corp1994-12-312008-07-30Canada
Gravol Tastefree Liquid Gel Capsulescapsule50 mgoralChurch & Dwight Canada Corp2002-09-23Not applicableCanada
Jamp-dimenhydrinate 50 Mg Tabletstablet50 mgoralJamp Pharma Corporation2003-07-31Not applicableCanada
Motion Sicknesstablet50 mg/1oralTarget Corporation1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralChain Drug Consortium, LLC2014-01-31Not applicableUs
Motion Sicknesstablet50 mg/1oralTOP CARE (Topco Associates LLC)2013-05-31Not applicableUs
Motion Sicknesstablet50 mg/1oralGREAT LAKES WHOLESALE, MARKETING, & SALES, INC.1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralFreds Inc2010-07-08Not applicableUs
Motion Sicknesstablet50 mg/1oralHarmon Store Inc.1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralWOONSOCKET PRESCRIPTION CENTER,INCORPORATED1992-12-01Not applicableUs
Motion Sicknesstablet50 mg/1oralMEIJER, INC.2014-03-28Not applicableUs
Motion Sicknesstablet50 mg/1oralL&R Distributors, Inc.1992-12-01Not applicableUs
Motion Sickness Children's Chewable Tabletstablet (chewable)15 mgoralTanta Pharmaceuticals IncNot applicableNot applicableCanada
Motion Sickness Original Formulatablet50 mg/1oralGood Sense (Geiss, Destin & Dunn, Inc.)2010-08-10Not applicableUs
Motion Sickness Original Formulatablet50 mg/1oralMc Kesson (Sunmark)2011-06-13Not applicableUs
Motion Sickness Original Formulatablet50 mg/1oralNational Distribution Network (Smart Choice)2014-06-30Not applicableUs
Motion Sickness Original Formulatablet50 mg/1oralCVS Pharmacy2014-04-15Not applicableUs
Motion Sickness Relieftablet50 mg/1oralWestern Family Foods, Inc.2010-07-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralChain Drug Marketing Association Inc1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralWal Mart Stores Inc1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralRite Aid1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralBetter Living Brands, Llc1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralHarmon Stores2015-03-31Not applicableUs
Motion Sickness Relieftablet50 mg/1oralWin Co Foods, Llc1992-12-01Not applicableUs
Motion Sickness Relieftablet50 mg/1oralAmerisource Bergen Drug Corporation (Good Neighbor Pharmacy) 243852010-07-09Not applicableUs
Motion Sickness Relief Liquid Gelscapsule50 mgoralAccucaps Industries LimitedNot applicableNot applicableCanada
Motion Sickness Relief Original Formulatablet50 mg/1oralCare One (American Sales Company)2010-07-15Not applicableUs
Motion Sickness Tab 50mgtablet50 mgoralDrug Trading Company Ltd.1977-12-311996-09-17Canada
Motion Sickness Tablets 50mgtablet50 mgoralD.C. Labs Limited1995-12-312005-07-19Canada
Nauseatoltablet (chewable)50 mgoralSandoz Canada Incorporated1979-12-31Not applicableCanada
Nauseatoltablet (chewable)15 mgoralSandoz Canada Incorporated1994-12-31Not applicableCanada
Nausex Tab 50mgtablet50 mgoralNobel Pharm Enr.1981-12-311998-08-14Canada
Orb-dimenhydrinate Tablets USPtablet50 mgoralOrbus Pharma IncNot applicableNot applicableCanada
Original Formula Motion Sickness Relieftablet50 mg/1oralMc Kesson (Health Mart)2012-06-26Not applicableUs
Original Formula Motion Sickness Relieftablet50 mg/1oralCardinal Health (Leader) 372052012-06-26Not applicableUs
Pac-kit Motion Sicknesstablet, coated50 mg/1oralAcme United Corporation2013-10-21Not applicableUs
Physicianscare Dimenhydrinate Motion Sickness Relieftablet, coated50 mg/1oralAcme United Corporation2013-10-05Not applicableUs
PMS-dimenhydrinate Syr 3mg/mlsyrup3 mgoralPharmascience Inc1996-08-23Not applicableCanada
PMS-dimenhydrinate Tab 50mgtablet50 mgoralPharmascience Inc1984-12-31Not applicableCanada
Riva-dimenhydrinate Tabletstablet50 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz Dimenhydrinatesuppository50 mgrectalSandoz Canada Incorporated1974-12-31Not applicableCanada
Sandoz Dimenhydrinatesuppository100 mgrectalSandoz Canada Incorporated1974-12-31Not applicableCanada
Sicknoltablet50 mgoralBromed Pharmaceuticals Inc.Not applicableNot applicableCanada
Teva-dimenatetablet50 mgoralTeva Canada Limited1967-12-31Not applicableCanada
Travamine Sup 50mgsuppository50 mgrectalIcn Canada Ltd.1979-12-312005-05-04Canada
Travamine Tab 50mgtablet50 mgoralIcn Canada Ltd.1962-12-312005-05-04Canada
Travel Easetablet50 mg/1oralBest Choice (Valu Merchandisers Company)2010-08-10Not applicableUs
Travel Sicknesstablet50 mg/1oralQUALITY CHOICE (Chain Drug Marketing Association)2010-07-14Not applicableUs
Travel Tabstablet50 mgoralTanta Pharmaceuticals Inc2010-01-07Not applicableCanada
Travel Tabs 50 mgtablet50 mgoralVita Health Products Inc1984-12-31Not applicableCanada
Travelmate Tab 50mgtablet50 mgoralShoppers Drug Mart Inc.1979-12-311998-08-14Canada
Travelmate-dimenhydrinate Tablets 50mgtablet50 mgoralKsl Pharmaceuticals1992-12-311997-08-08Canada
Traveltabs 50mgtablet50 mgoralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1972-12-312002-07-31Canada
Wal-dramtablet50 mg/1oralWALGREEN CO.1992-12-01Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
GravolChurch & Dwight
VertirosanAstellas
Vomex AAstellas
XamaminaAdilna
Brand mixtures
NameLabellerIngredients
Gravergol CapsulesCan Med Pharma Inc.
SaltsNot Available
Categories
UNIIJB937PER5C
CAS number523-87-5
WeightAverage: 469.964
Monoisotopic: 469.188067494
Chemical FormulaC24H28ClN5O3
InChI KeyInChIKey=DKHVTDUUNTVKOW-UHFFFAOYSA-N
InChI
InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10,13)
IUPAC Name
8-chloro-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-ide; [2-(diphenylmethoxy)ethyl]dimethylazanium
SMILES
CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Alkaloid or derivatives
  • Xanthine
  • Purinone
  • 6-oxopurine
  • Purine
  • Imidazopyrimidine
  • Benzylether
  • Pyrimidone
  • Pyrimidine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Vinylogous amide
  • Quaternary ammonium salt
  • Imidazole
  • Azole
  • Urea
  • Lactam
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Organic zwitterion
  • Aromatic homomonocyclic compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkNot Available
External Descriptors
Pharmacology
IndicationUsed for treating vertigo, motion sickness, and nausea associated with pregnancy.
PharmacodynamicsDimenhydrinate is an antiemetics drug combination that contains diphenhydramine and theophylline. It is not effective in the treatment of nausea associated with cancer chemotherapy. Dimenhydrinate directly inhibits the stimulation of certain nerves in the brain and inner ear to suppress nausea, vomiting, dizziness, and vertigo. Diphenhydramine and dimenhydinate both reduce vestibular neuronal excitation due to angular or linear acceleration motions.
Mechanism of actionThe mechanism by which some antihistamines exert their antiemetic, anti–motion sickness, and antivertigo effects is not precisely known but may be related to their central anticholinergic actions. They diminish vestibular stimulation and depress labyrinthine function. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Dimenhydrinate is a competitive antagonist at the histamine H1 receptor, which is widely distributed in the human brain. Dimenhydrinate's anti-emetic effect is probably due to H1 antagonism in the vestibular system in the brain.
Related Articles
AbsorptionWell absorbed after oral administration.
Volume of distributionNot Available
Protein binding98 to 99%.
Metabolism

Hepatic (cytochrome P-450 system).

Route of eliminationNot Available
Half life1 to 4 hours
ClearanceNot Available
ToxicitySymptoms of overdose include delerium, hallucinations, and excitment. Patients may be violent and confused.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9975
Blood Brain Barrier+0.8551
Caco-2 permeable+0.5198
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor INon-inhibitor0.6923
P-glycoprotein inhibitor IIInhibitor0.6502
Renal organic cation transporterNon-inhibitor0.6507
CYP450 2C9 substrateNon-substrate0.7536
CYP450 2D6 substrateNon-substrate0.8181
CYP450 3A4 substrateSubstrate0.7086
CYP450 1A2 substrateInhibitor0.5287
CYP450 2C9 inhibitorNon-inhibitor0.6308
CYP450 2D6 inhibitorNon-inhibitor0.8589
CYP450 2C19 inhibitorNon-inhibitor0.5817
CYP450 3A4 inhibitorNon-inhibitor0.9028
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5738
Ames testNon AMES toxic0.5629
CarcinogenicityNon-carcinogens0.7548
BiodegradationNot ready biodegradable0.8211
Rat acute toxicity2.4087 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5364
hERG inhibition (predictor II)Inhibitor0.5405
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Alra laboratories inc
  • Heather drug co inc
  • Nexgen pharma inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral25 mg/1
Liquidoral15 mg
Injection, solutionintramuscular; intravenous50 mg/mL
Tablet, film coatedoral50 mg/1
Liquidintravenous10 mg
Liquidintramuscular; intravenous50 mg
Solutionintramuscular; intravenous50 mg
Tabletoral50 mg
Tabletoral50.0 mg
Tablet, chewableoral25 mg/1
Tablet, chewableoral50 mg/1
Capsule
Capsule (sustained-release)oral75 mg
Suppositoryrectal100 mg
Tabletoral15 mg
Solutionintramuscular50 mg
Tablet (combined release)oral100 mg
Solutionintravenous10 mg
Suppositoryrectal25 mg
Syruporal15 mg
Tablet (extended-release)oral75 mg
Tabletoral25 mg
Capsuleoral50 mg
Tablet (chewable)oral15 mg
Tablet (chewable)oral50 mg
Tablet, coatedoral50 mg/1
Syruporal3 mg
Suppositoryrectal50 mg
Tabletoral50 mg/1
Prices
Unit descriptionCostUnit
Dimenhydrinate 50 mg/ml vial5.7USD ml
Dimenhydrinate I.M. 50 mg/ml1.17USD ml
Meclizine 12.5 mg tablet0.62USD tablet
Dramamine less drowsy tablet0.42USD tablet
Dimenhydrinate I.V. 10 mg/ml0.32USD ml
Dramamine 50 mg tablet0.28USD tablet
Novamine 15% iv solution0.09USD ml
Dimenhydrinate 100% powder0.07USD g
Driminate 50 mg tablet0.05USD tablet
Dimenhydrinate 50 mg tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point102.5-104Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.
water solubility3000 mg/LMERCK INDEX (1996); approx.
logP-0.39Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00125 mg/mLALOGPS
logP2.67ALOGPS
logP3.65ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area13.67 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity90.94 m3·mol-1ChemAxon
Polarizability30.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co.
Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.

General References
  1. Takeda N, Morita M, Hasegawa S, Horii A, Kubo T, Matsunaga T: Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol Suppl. 1993;501:10-5. [PubMed:8447218 ]
  2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984 ]
  3. Jaju BP, Wang SC: Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther. 1971 Mar;176(3):718-24. [PubMed:4329456 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 56:22.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dimenhydrinate.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Dimenhydrinate.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dimenhydrinate.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Dimenhydrinate.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dimenhydrinate.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Dimenhydrinate.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dimenhydrinate.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dimenhydrinate.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dimenhydrinate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dimenhydrinate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dimenhydrinate.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dimenhydrinate.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dimenhydrinate.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dimenhydrinate.
AmoxapineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Dimenhydrinate.
AmphetamineAmphetamine may decrease the sedative activities of Dimenhydrinate.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dimenhydrinate.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Dimenhydrinate.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dimenhydrinate.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Dimenhydrinate.
AzelastineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dimenhydrinate.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dimenhydrinate.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dimenhydrinate.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dimenhydrinate.
BenzphetamineBenzphetamine may decrease the sedative activities of Dimenhydrinate.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dimenhydrinate.
Benzylpenicilloyl PolylysineDimenhydrinate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Dimenhydrinate.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
BrimonidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dimenhydrinate.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dimenhydrinate.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Dimenhydrinate.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dimenhydrinate.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Dimenhydrinate.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dimenhydrinate.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dimenhydrinate.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Dimenhydrinate.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dimenhydrinate.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Dimenhydrinate.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dimenhydrinate.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dimenhydrinate.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dimenhydrinate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dimenhydrinate.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dimenhydrinate.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dimenhydrinate.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dimenhydrinate.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dimenhydrinate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dimenhydrinate.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dimenhydrinate.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dimenhydrinate.
ChlorphenamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Dimenhydrinate.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dimenhydrinate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dimenhydrinate.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dimenhydrinate.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dimenhydrinate.
CitalopramThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dimenhydrinate.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dimenhydrinate.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dimenhydrinate.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Dimenhydrinate.
ClomipramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dimenhydrinate.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dimenhydrinate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dimenhydrinate.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dimenhydrinate.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dimenhydrinate.
CyclizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dimenhydrinate.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dimenhydrinate.
DantroleneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dimenhydrinate.
DapoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Dimenhydrinate.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dimenhydrinate.
DesipramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dimenhydrinate.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Dimenhydrinate.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimenhydrinate.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dimenhydrinate.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Dimenhydrinate.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dimenhydrinate.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dimenhydrinate.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dimenhydrinate.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dimenhydrinate.
DifenoxinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dimenhydrinate.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dimenhydrinate.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dimenhydrinate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dimenhydrinate.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Dimenhydrinate.
DoxepinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DoxylamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Dimenhydrinate.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dimenhydrinate.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dimenhydrinate.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dimenhydrinate.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dimenhydrinate.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Dimenhydrinate.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dimenhydrinate.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dimenhydrinate.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dimenhydrinate.
EscitalopramThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dimenhydrinate.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dimenhydrinate.
EthanolDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dimenhydrinate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimenhydrinate.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimenhydrinate.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dimenhydrinate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dimenhydrinate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dimenhydrinate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dimenhydrinate.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Dimenhydrinate.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Dimenhydrinate.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Dimenhydrinate.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dimenhydrinate.
EtoperidoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dimenhydrinate.
EzogabineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dimenhydrinate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dimenhydrinate.
FenfluramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dimenhydrinate.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dimenhydrinate.
FlibanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dimenhydrinate.
FlunarizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dimenhydrinate.
FluoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dimenhydrinate.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dimenhydrinate.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dimenhydrinate.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dimenhydrinate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Dimenhydrinate.
FluvoxamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dimenhydrinate.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dimenhydrinate.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dimenhydrinate.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dimenhydrinate.
GuanfacineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dimenhydrinate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dimenhydrinate.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dimenhydrinate.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dimenhydrinate.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dimenhydrinate.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dimenhydrinate.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dimenhydrinate.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Dimenhydrinate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
HydroxyzineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dimenhydrinate.
IndalpineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dimenhydrinate.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dimenhydrinate.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dimenhydrinate.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dimenhydrinate.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dimenhydrinate.
LevetiracetamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dimenhydrinate.
LevocabastineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dimenhydrinate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dimenhydrinate.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dimenhydrinate.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Dimenhydrinate.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dimenhydrinate.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Dimenhydrinate.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dimenhydrinate.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dimenhydrinate.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dimenhydrinate.
Lu AA21004The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dimenhydrinate.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dimenhydrinate.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Dimenhydrinate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dimenhydrinate.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Dimenhydrinate.
MephentermineMephentermine may decrease the sedative activities of Dimenhydrinate.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dimenhydrinate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dimenhydrinate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dimenhydrinate.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dimenhydrinate.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dimenhydrinate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dimenhydrinate.
MethamphetamineMethamphetamine may decrease the sedative activities of Dimenhydrinate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dimenhydrinate.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dimenhydrinate.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dimenhydrinate.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dimenhydrinate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dimenhydrinate.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dimenhydrinate.
MethsuximideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dimenhydrinate.
MetyrosineDimenhydrinate may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dimenhydrinate.
MilnacipranThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
MirtazapineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dimenhydrinate.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Dimenhydrinate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dimenhydrinate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
NabiloneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dimenhydrinate.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dimenhydrinate.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dimenhydrinate.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Dimenhydrinate.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dimenhydrinate.
OlanzapineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dimenhydrinate.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dimenhydrinate.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Dimenhydrinate.
OrphenadrineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dimenhydrinate.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Dimenhydrinate.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dimenhydrinate.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dimenhydrinate.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dimenhydrinate.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dimenhydrinate.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dimenhydrinate.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dimenhydrinate.
ParaldehydeDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dimenhydrinate.
ParoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dimenhydrinate.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dimenhydrinate.
PerampanelThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Dimenhydrinate.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dimenhydrinate.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dimenhydrinate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dimenhydrinate.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Dimenhydrinate.
PhenterminePhentermine may decrease the sedative activities of Dimenhydrinate.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dimenhydrinate.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dimenhydrinate.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dimenhydrinate.
PipotiazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pomalidomide.
PramipexoleDimenhydrinate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dimenhydrinate.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Dimenhydrinate.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dimenhydrinate.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dimenhydrinate.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Dimenhydrinate.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dimenhydrinate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimenhydrinate.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dimenhydrinate.
PromethazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dimenhydrinate.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dimenhydrinate.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Dimenhydrinate.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dimenhydrinate.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Dimenhydrinate.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dimenhydrinate.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dimenhydrinate.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dimenhydrinate.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dimenhydrinate.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dimenhydrinate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dimenhydrinate.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dimenhydrinate.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Dimenhydrinate.
RopiniroleDimenhydrinate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dimenhydrinate.
RotigotineDimenhydrinate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dimenhydrinate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dimenhydrinate.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimenhydrinate.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dimenhydrinate.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Dimenhydrinate.
SertralineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dimenhydrinate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Dimenhydrinate.
StiripentolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dimenhydrinate.
SuvorexantThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dimenhydrinate.
TetrabenazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dimenhydrinate.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dimenhydrinate.
ThalidomideDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dimenhydrinate.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dimenhydrinate.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dimenhydrinate.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dimenhydrinate.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dimenhydrinate.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dimenhydrinate.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Dimenhydrinate.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dimenhydrinate.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dimenhydrinate.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dimenhydrinate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dimenhydrinate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dimenhydrinate.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dimenhydrinate.
TrazodoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dimenhydrinate.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dimenhydrinate.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dimenhydrinate.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dimenhydrinate.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dimenhydrinate.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dimenhydrinate.
VigabatrinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Dimenhydrinate.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dimenhydrinate.
ZiconotideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dimenhydrinate.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Dimenhydrinate.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dimenhydrinate.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dimenhydrinate.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dimenhydrinate.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Dimenhydrinate.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dimenhydrinate.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23